Showing 4301-4310 of 9578 results for "".
- COVID-19 By the Numbers: April 7 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-7-edition/2460341/The peak for medical resource utilization related to COVID-19 in the US is estimated to hit on April 15, and deaths will peak on April 16, according to the Institute for Health Metrics and Evaluation (IHME), an independent population health research center at UW Medicine at the University of
- Evolve BioSystems and Janssen to Study the Impact of B. infantis EVC001 for AD Prevention in Infantshttps://practicaldermatology.com/news/evolve-biosystems-and-janssen-to-study-the-impact-of-b-infantis-evc001-for-ad-prevention-in-infants/2460324/Evolve BioSystems, Inc. and Janssen Research & Development, LLC, are partnering to conduct a study looking at the potential role of B. infantis EVC001 in preventing early childhood atopic dermatitis (AD). The study will assess the effects of introducing a specific gut
- New AAAHC COVID-19 Guidelines Call for Postponing Elective or Non-Essential Visits and Surgerieshttps://practicaldermatology.com/news/new-aaahc-covid-19-guidelines-call-for-postponing-elective-or-non-essential-visits-and-surgeries/2460323/The Accreditation Association for Ambulatory Health Care (AAAHC) is calling for the postponement of elective or non-essential visits or surgeries in their newly released guidelines. For patients that require an office visit, increas
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- 30% of Americans’ Jobs Negatively Impacted by COVID-19, Economic Fallouthttps://practicaldermatology.com/news/30-of-americans-jobs-negatively-impacted-by-covid-19-economic-fallout/2460317/While 35 percent of 1,000 Americans surveyed by LendEDU say that that their jobs have not been impacted by the Coronavirus, six percent report losing their job, 13 percent report that hours have been partially cut, and 11 percent have had hours cut entirely, though they still have their jobs.
- Nation's Largest Nurses Union to Congress: Ensure Standards for Healthcare Workers to Avoid COVID-19https://practicaldermatology.com/news/nations-largest-nurses-union-to-congress-ensure-standards-for-healthcare-workers-to-avoid-covid-19/2460314/National Nurses United, the largest union of registered nurses, is calling on Congress to mandate that the Occupational Safety and Health Administration promulgate an emergency temporary standard for health care workers in the third COVID-19 stimulus package currently being negotiated.
- First Patient Enrolled in Avita Medical’s Pivotal Study Evaluating Recell System for Soft Tissue Reconstructionhttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-medicals-pivotal-study-evaluating-recell-system-for-soft-tissue-reconstruction/2460294/Avita Medical Limited enrolled the first patient in a study evaluating the Recell System for Soft Tissue Reconstruction at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ. The prospective multi-center trial of at least 65 patients will compare the clinical per
- Acne Pipeline Watch: Dermata Therapeutics Completes Enrollment in Phase 2b Trial of Once-Weekly Topical DMT310 for Acnehttps://practicaldermatology.com/news/acne-pipeline-watch-dermata-therapeutics-completes-enrollment-in-phase-2b-trial-of-once-weekly-topical-dmt310-for-acne/2460282/Dermata Therapeutics, LLC completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients. The Phase 2b trial enrolled 182 patients randomly in two group
- Aerolase and Eucerin Join Forces to Optimize Patient Outcomes in Laser Treatmentshttps://practicaldermatology.com/news/aerolase-and-eucerin-join-forces-to-optimize-patient-outcomes-in-laser-treatments-1/2460277/Aerolase and Eucerin are working together to optimize laser treatment protocols in the D-A-CH-region (Germany-Austria-Switzerland). Furthermore, both companies will develop therapies for adjunctive care post-laser treatments. Both companies will also conduct a joint symposium
- Dr. Susan Weinkle Honored with Outstanding Educator & Mentor in Dermatology Award at ODAChttps://practicaldermatology.com/news/dr-susan-weinkle-honored-with-outstanding-educator-mentor-in-dermatology-award-at-odac/2460259/Susan H. Weinkle, MD, was awarded the Outstanding Educator & Mentor in Dermatology Award by the ODAC Dermatology, Aesthetic & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD), at the conference held January 17-20 in Orlando, FL. The award